Dasatinib Monohydrate is a potent tyrosine kinase inhibitor primarily indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. As an essential… Read more
Dasatinib Monohydrate is a potent tyrosine kinase inhibitor primarily indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. As an essential anticancer agent, it functions by blocking specific signaling pathways, such as BCR-ABL, to inhibit cancer cell proliferation. To support critical pharmaceutical development and manufacturing, laboratories rely on high-quality reference standards of this drug. This category provides the API alongside related impurities, metabolites, and stable isotope labelled compounds required for rigorous analytical testing and quality control. These materials are vital for accurate impurity profiling, method validation, and stability studies, enabling the precise identification and quantification of degradation products within formulations. By providing consistent reference materials, these products assist in satisfying complex regulatory requirements for pharmaceutical analysis.